ArticleScientific reports2026
Facile Cobalt-supported Zeolite 4 A as ecofriendly catalyst to prepare 2-Furyl- hydrazine-1-carbothioamides and 1,2,4 Triazole-3-thiones with anticancer investigation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, crystalline porous zeolite materials have been extensively investigated owing to their distinct characteristics, such as high surface area, pore volume, size, and thermal stability. In this work, 500 nm to 1 μm sized thermally stable cobalt-supported zeolite 4 A was developed via impregnation method, employed as an efficient and reusable catalyst in synthesizing novel thiosemicarbazide and 1,2,4 triazole derivatives using Co-Zeolite 4 A in ethanol: water (1:1) as a green solvent, and found most active among Ni and Fe-supported Zeolite 4 A, with 89% yield. FT-IR, XRD, and BET data revealed characteristic metal-support interactions, crystalline domains, and reduction in surface area (10.1 to 9.4 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.